Article Text

Download PDFPDF
Original article
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes
  1. David S Williams1,2,
  2. Dmitri Mouradov3,4,
  3. Robert N Jorissen3,4,
  4. Marsali R Newman1,
  5. Elham Amini5,
  6. David K Nickless6,
  7. Julie A Teague6,
  8. Catherine G Fang2,
  9. Michelle Palmieri3,4,
  10. Marie J Parsons4,
  11. Anuratha Sakthianandeswaren3,4,
  12. Shan Li4,
  13. Robyn L Ward7,
  14. Nicholas J Hawkins8,
  15. Ian Faragher9,
  16. Ian T Jones10,
  17. Peter Gibbs3,4,11,12,
  18. Oliver M Sieber3,4,13,14
  1. 1 Department of Pathology, Austin Health, Heidelberg, Victoria, Australia
  2. 2 Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
  3. 3 Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
  4. 4 Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
  5. 5 Clinipath Pathology, Sonic Healthcare, Perth, Western Australia, Australia
  6. 6 Australian Clinical Labs, The Northern Hospital, Epping, Victoria, Australia
  7. 7 Office of the Deputy Vice-Chancellor (Research), The University of Queensland, Brisbane, Queensland, Australia
  8. 8 Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia
  9. 9 Department of Surgery, Western Health, Footscray, Australia
  10. 10 Department of Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia
  11. 11 Department of Medical Oncology, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
  12. 12 Department of Medical Oncology, Western Health, Footscray, Victoria, Australia
  13. 13 Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
  14. 14 School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia
  1. Correspondence to Dr Oliver M Sieber, Systems Biology and Personalised Medicine Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; oliver.sieber{at}wehi.edu.au

Footnotes

  • Contributors Conceptualisation: DSW, DM, RNJ and OMS; methodology and data acquisition: DSW,DM, RNJ, MRN, EA, DKN, JAT, CGF, MP, MJP, AS, SL and OMS; data curation and statistical analysis: DSW, DM, RNJ, RLW, NJH, IF, ITJ, PG and OMS; resources: DSW, RLW, NJH, IF, ITJ, PG and OMS; writing (original draft): DSW,DM, RNJ and OMS; writing (review and editing): MRN, EA, DKN, JAT, CGF, MP, MJP, AS, SL, RLW, NJH, IF, ITJ and PG; supervision: DSW and OMS; funding acquisition: DSW and OMS.

  • Funding This work was supported by a Cancer Australia Project Grant (APP1120882), a Cancer Council Victoria Grant-in-Aid (1060964), the Victorian Government’s Operational Infrastructure Support Program, a University of Melbourne Department of Pathology Career Development Award and an Austin Medical Research Foundation Project Grant. OMS is a NHMRC RD. Wright Biomedical Fellow (APP1062226). MP is supported by a Cancer Therapeutics CRC (CTx) Top Up PhD Scholarship and Australian Government Research Training Program Scholarship.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval WEHI HREC 12/19.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Not applicable.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Conceptualisation: DSW, DM, RNJ and OMS; methodology and data acquisition: DSW,DM, RNJ, MRN, EA, DKN, JAT, CGF, MP, MJP, AS, SL and OMS; data curation and statistical analysis: DSW, DM, RNJ, RLW, NJH, IF, ITJ, PG and OMS; resources: DSW, RLW, NJH, IF, ITJ, PG and OMS; writing (original draft): DSW,DM, RNJ and OMS; writing (review and editing): MRN, EA, DKN, JAT, CGF, MP, MJP, AS, SL, RLW, NJH, IF, ITJ and PG; supervision: DSW and OMS; funding acquisition: DSW and OMS.

  • Funding This work was supported by a Cancer Australia Project Grant (APP1120882), a Cancer Council Victoria Grant-in-Aid (1060964), the Victorian Government’s Operational Infrastructure Support Program, a University of Melbourne Department of Pathology Career Development Award and an Austin Medical Research Foundation Project Grant. OMS is a NHMRC RD. Wright Biomedical Fellow (APP1062226). MP is supported by a Cancer Therapeutics CRC (CTx) Top Up PhD Scholarship and Australian Government Research Training Program Scholarship.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval WEHI HREC 12/19.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Not applicable.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.